Header Images

ITOR Collaborators

ITOR Advances Cancer Care through Collaboration & Strategic Partnerships

The ability of the Institute for Translational Oncology Research (ITOR) of Greenville Health System (GHS) to achieve its bold vision - to be an international destination center for the development and delivery of innovative, personalized cancer therapies - is accelerated through collaborative partnerships. These strategic relationships advance key initiatives, such as more efficient drug development and the discovery of more effective new treatments for cancer, while helping to fulfill a primary ITOR aspiration - the establishment of an unprecedented translational research model of the future.

The Institute's full integration with Greenville Health System and Cancer Centers of the Carolinas - and a wide spectrum of strategic alliances and relationships with the pharmaceutical industry, research universities, private sector innovation companies, national / international networks, major cancer centers, institutes and government agencies - is vital to its continuing success and evolution. This collaborative model paves the way for breakthrough cancer therapy discoveries.

The extended ITOR of GHS team of collaborators and partners continues to grow and evolve as ITOR remains focused on achieving the most efficient translation of basic science into the clinical investigation of cancer and the development of new treatments for cancer. By discovering and developing clinically meaningful molecular and genomic markers with prognostic and predictive capabilities, and by creating an environment for the education and training of medical professionals in translational and personalized medicine, ITOR advances cancer care on multiple levels.

Ultimately, ITOR's strategic relationships with a wide variety of collaborative partners enhances and increases the Institute's clinical trial offerings. The Institute's focus on efficient and effective drug development and the discovery of new treatments for cancer allows patients in the Western Carolinas and Northeast Georgia to remain closer to home for some of the most advanced cancer therapy capabilities offered anywhere in the world.